购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空
筛选
已筛选:全部清除
TargetMol | Tags 通过 靶点 筛选
  • JAK
    (1)
  • Others
    (7)
TargetMol | Tags 通过 货期 筛选
  • 1-2周
    (1)
  • 8-10周
    (2)
  • 3-6月
    (2)
  • 待询
    (1)
抑制剂&激动剂
细分筛选
搜索结果
TargetMol产品目录中 "dpp iv in 1"的结果
筛选
搜索结果
TargetMol产品目录中 "

dpp iv in 1

"的结果
  • 抑制剂&激动剂
    11
    TargetMol | Inhibitors_Agonists
  • 多肽产品
    1
    TargetMol | Peptide_Products
  • 天然产物
    1
    TargetMol | Natural_Products
  • DPP-IV-IN-1
    T10082625110-37-4In house
    DPP-IV-IN-1 is an effective inhibitor of dipeptidyl peptidase IV (DPP-IV), a serine protease (IC50: 4.6 nM).
    • ¥ 10600
    3-6月
    规格
    数量
  • DPP IV/hCA II-IN-1
    T749782836996-95-1
    DPP IV hCA II-IN-1 是一种有效的选择性二肽肽酶 IV (DPP IV) 和碳酸酐酶 (CA) 抑制剂,抑制 DPP IV 的 IC50值为 0.049 μM, 抑制 CA II、CA VB、CA VA、CA IX、CA I 和 CA IV 的 Ki 值分别为 0.0361、0.0428、0.0941、0.1328、0.2615 和 3.034 μM。
    • 待询
    3-6月
    规格
    数量
  • Talabostat
    T37861149682-77-9
    Talabostat (PT100, Val-boroPro) is a potent, nonselective and orally available dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 0.18 nM. Talabostat is a nonselective DPP-IV inhibitor, inhibiting DPP8 9, FAP, DPP2 and some other DASH family enzymes essentially as potently as it inhibits DPP-IV[1]. Talabostat stimulates the immune system by triggering a proinflammatory form of cell death in monocytes and macrophages known as pyroptosis. The inhibition of two serine proteases, DPP8 and DPP9, activates the proprotein form of caspase-1 independent of the inflammasome adaptor ASC[2]. Talabostat competitively inhibits the dipeptidyl peptidase (DPP) activity of FAP and CD26 DPP-IV, and there is a high-affinity interaction with the catalytic site due to the formation of a complex between Ser630 624 and the boron of talabostat[3]. Talabostat can stimulate immune responses against tumors involving both the innate and adaptive branches of the immune system. In WEHI 164 fibrosarcoma and EL4 and A20 2J lymphoma models, PT-100 causes regression and rejection of tumors. The antitumor effect appears to involve tumor-specific CTL and protective immunological memory. Talabostat treatment of WEHI 164-inoculated mice increases mRNA expression of cytokines and chemokines known to promote T-cell priming and chemoattraction of T cells and innate effector cells[3]. Talabostat treated mice show significant less fibrosis and FAP expression is reduced. Upon PT100 treatment, significant differences in the MMP-12, MIP-1α, and MCP-3 mRNA expression levels in the lungs are also observed. Treatment with PT100 in this murine model of pulmonary fibrosis has an anti-fibro-proliferative effect and increases macrophage activation[4]. [1]. Connolly BA, et al. Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potencyand in vivo efficacy and safety. J Med Chem. 2008 Oct 9;51(19):6005-13. [2]. Okondo MC, et al. DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nat Chem Biol. 2017 Jan;13(1):46-53. [3]. Adams S, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004 Aug 1;64(15):5471-80. [4]. Egger C, et al. Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol. 2017 Aug 15;809:64-72.
    • ¥ 931
    待询
    规格
    数量
  • ASP-8497
    UNII-GC7THT248G, ASP8497, ASP 8497
    T30169651055-26-4
    ASP8497 is a potent, long-acting DPP-IV inhibitor that improves glucose tolerance by elevating GLP-1 levels in a glucose-dependent insulin-stimulating manner. The compound is used as a therapeutic agent for impaired glucose tolerance and type 2 diabetes.
    • ¥ 15000
    8-10周
    规格
    数量
  • Vildagliptin dihydrate
    T610762133364-01-7
    Vildagliptin dihydrate (LAF237 dihydrate) is a powerful and stable dipeptidyl peptidase IV (DPP-IV) inhibitor, demonstrating selectivity with an IC50 of 3.5 nM in human Caco-2 cells. This compound exhibits exceptional oral bioavailability and significant antihyperglycemic activity [1].
    • ¥ 14900
    1-2周
    规格
    数量
  • fotagliptin benzoate
    T738751403496-40-1
    Fotagliptin benzoate,作为一种二肽基肽酶IV (DPP-4) 抑制剂(IC50=2.27 nM),在大鼠和狗中展现了安全性,适用于2型糖尿病的研究。
    • 待询
    规格
    数量
  • DPP-4/GPR119 modulator 1
    T745282411099-68-6
    DPP-4 GPR119 modulator 1 (Compound 22) 是一种具有口服活性的二肽基肽酶 IV (DPP-IV) 抑制剂和 GPR119激动剂。DPP-4 GPR119 modulator 1 具有降血糖作用,抑制hERG 通道,IC50值为 4.9 µM。DPP-4 GPR119 modulator 1 可用于糖尿病的研究。
    • 待询
    规格
    数量
  • DPP
    T796082668267-47-6
    DPP,一种含紫檀芪衍生轴向配体的铂(IV)络合物,能够抑制乳腺癌(BC)细胞的JAK2-STAT3通路并显示出抗增殖特性。它通过激活caspase-3和裂解聚ADP-核糖聚合酶诱导细胞凋亡(apoptosis),同时促进树突状细胞成熟及抗原呈现功能,并已证明体内具有安全性。
    • 待询
    8-10周
    规格
    数量
  • Lyciumamide A
    T818981647111-40-7
    DPP-IV-IN-5,一种从枸杞果实中分离得到的化合物,对过氧化物酶体增殖物激活受体(PPARγ)展示中等拮抗活性,其EC50值介于10.09至44.26 μM,同时对二肽基肽酶-4 (DPPIV)亦有抑制作用,IC50值为47.13 μM。
    • 待询
    规格
    数量
  • Dipeptidyl peptidase IV
    二肽基肽酶IV,DPP-IV
    T8937354249-88-6
    Dipeptidyl peptidaseIV (DPP-IV) 是一种具有多重生物功能的蛋白酶,不仅能促使诸如胰高血糖素样肽 1 (GLP-1) 和葡萄糖依赖性胰岛素样多肽 (GIP) 等肠促胰岛素激素失活,还能作为多种细胞外分子的结合蛋白和配体.此外,Dipeptidyl peptidaseIV 在糖尿病和肿瘤领域的研究中也显示出其重要应用价值.
    • 待询
    规格
    数量
  • VAMP
    TP3084
    VAMP 是一种四肽和竞争性二肽基肽酶 IV (DPP-IV) 抑制剂,其 IC50 为 1.00 μM,Kd 为 6.89 μM。VAMP 有效靶向 DPP-IV-GLP-1 轴,适用于 2 型糖尿病的研究。
    • 待询
    规格
    数量
没有更多数据了